19.12.2020, 05:51
Meine größte Sorge um den Elispot ist - in mehreren Studien wurde gesagt, dass er nicht zwischen neuer und aktiver Infektion unterscheiden kann.
---
"The above results suggest that the iSpot Lyme assay is a highly sensitive in vitro assay for the detection of specific T cell immunity to Borrelia infection. However, since IFN-γ is secreted by both recently activated T effector cells and resting memory T cells, the iSpot Lyme assay cannot distinguish between active Borrelia infection and prior exposure. There is currently no standard laboratory test to distinguish active Borrelia infection from prior exposure [38]"
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3972671/
---
At present, IFN-γ ELISPOT cannot be used in routine practice because its role has only been established as a witness of Borrelia exposure. Specificity, cut-offs and reproducibility require more investigations.
https://www.sciencedirect.com/science/ar...3X1930388X
---
"The above results suggest that the iSpot Lyme assay is a highly sensitive in vitro assay for the detection of specific T cell immunity to Borrelia infection. However, since IFN-γ is secreted by both recently activated T effector cells and resting memory T cells, the iSpot Lyme assay cannot distinguish between active Borrelia infection and prior exposure. There is currently no standard laboratory test to distinguish active Borrelia infection from prior exposure [38]"
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3972671/
---
At present, IFN-γ ELISPOT cannot be used in routine practice because its role has only been established as a witness of Borrelia exposure. Specificity, cut-offs and reproducibility require more investigations.
https://www.sciencedirect.com/science/ar...3X1930388X